Market analysts have recommended subscribing to the issue, noting that Molbio Diagnostics’ valuations are broadly in line with industry benchmarks. The company is also being offered at a discount to the average P/E multiple of 64.9x for its listed peers, according to analysts.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.